ImmunityBio announced this morning that enrollment for its Anktiva therapy trial in non-muscle-invasive bladder cancer exceeded expectations, clearing a key threshold ahead of schedule. This achievement enables the company to prepare a biologics licensing application for submission to the FDA by year’s end. In parallel, the company reported that its CAR-NK therapy demonstrated 100% disease control in the first four patients treated for Non-Hodgkin lymphoma, marking a significant proof-of-concept for its next-generation immuno-oncology platform and signaling potential expansion beyond its lead program.

Preliminary financial results for fiscal 2025 revealed net product revenue of approximately $113 million, representing a 700% year-over-year increase driven by accelerating adoption of Anktiva. Fourth-quarter net product revenue reached $38.3 million, up 431% versus the same period in 2024 and 20% sequentially. Unit volume growth for the quarter was 54% higher than the third quarter, reflecting strong momentum in physician prescribing and patient uptake following recent international approvals.

With roughly $800 million in net cash on the balance sheet and no debt, ImmunityBio is well-funded to advance its pipeline through multiple clinical inflection points. The company’s market capitalization stands at nearly $5.3 billion, a valuation that investors view as justified given its pharmaceutical revenue runway and promising oncology data. Analysts remain bullish, citing the potential for additional label expansions in indications such as non-small cell lung cancer and approved use in the Saudi market as further catalysts.